NURSING DOMAIN
Published February 5, 2024 | Version v1
Journal article Open

Medications for Managing Emphysema: A Comprehensive Guide

Authors/Creators

Description

Emphysema is a chronic respiratory condition manifested by the gradual destruction of lung tissue, resulting in difficulty regarding breathing. Bronchodilators perform by relaxing g the smooth muscles of the airways, causing it easier for individuals with emphysema to breathe. There are two main types of bronchodilator namely Vantin cholinergic and beta _ agonists. Beta_ agonist namely albuterol and salmeterol activate beta receptors in the airways, resulting in bronchial dilatation and enhanced airflow. Anticholinergic namely tiotropium stop the action of acetyl. Choline, a neurotransmitter that constric the airways. Anticholinergic enhances brochure dilatation and easy breathing difficulties also. Inhaled corticosteroids namely budesonide and flymuticasone are frequently prescribed along with bronchi dilator. Phospho desperate _ 4 (PDE _ 4) inhibitors (Roflumilast) is used regarding the treatment of severe emphysema. Roflumilast assists in decreasing inflammation and relax the airways by inhibiting the action. Of PDE _ 4, an enzyme participated in the inflammatory process. In advanced stages of emphysema, if oxygen levels in the blood are low, supplemental oxygen plays an important role. Administered through nasal prognosis or masks, oxygen therapy assists in increasing oxygenation, alleviate symptoms and increasing overall quality. Finally it is concluded that medications play an important role in managing symptoms and slowing down disease progression that is emphysema.

Files

Medications for Managing Emphysema -Formatted Paper.pdf

Files (188.9 kB)

Additional details

References

  • 1. Rustagi, N., Singh, S., Dutt, N., Kuwal, A., Chaudhry, K., Shekhar, S., & Kirubakaran, R. (2019). Efficacy and safety of stent, valves, vapour ablation, coils and sealant therapies in advanced emphysema: a meta-analysis. Turkish thoracic journal, 20(1), 43.
  • 2. Fernandez-Bussy, S., Labarca, G., & Herth, F. J. (2018, December). Bronchoscopic lung volume reduction in patients with severe emphysema. In Seminars in Respiratory and Critical Care Medicine (Vol. 39, No. 06, pp. 685-692). Thieme Medical Publishers.
  • 3. Dunlap, D. G., Semaan, R., Riley, C. M., & Sciurba, F. C. (2019). Bronchoscopic device intervention in chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine, 25(2), 201-210.
  • 4. Asri, H., & Zegmout, A. (2018). The two major complications of tobacco in a single image!. The Pan African Medical Journal, 30, 252-252.
  • 5. Thomson, N. C. (2018). Challenges in the management of asthma associated with smoking-induced airway diseases. Expert opinion on pharmacotherapy, 19(14), 1565-1579.
  • 6. Zhang, H., Dong, L., Kang, Y. K., Lu, Y., Wei, H. H., Huang, J., ... & Huang, K. (2018). Epidemiology of chronic airway disease: results from a cross-sectional survey in Beijing, China. Journal of Thoracic Disease, 10(11), 6168.
  • 7. Mouronte-Roibás, C., Fernández-Villar, A., Ruano-Raviña, A., Ramos-Hernández, C., Tilve-Gómez, A., Rodríguez-Fernández, P., ... & Leiro-Fernández, V. (2018). Influence of the type of emphysema in the relationship between COPD and lung cancer. International Journal of Chronic Obstructive Pulmonary Disease, 3563-3570.
  • 8. Harrison, R., Knowles, S., & Doherty, C. (2020). Surgical Emphysema in a Pediatric Tertiary Referral Center. Pediatric Emergency Care, 36(1), e21-e24.
  • 9. Buttar, B. S., & Bernstein, M. (2018). The importance of early identification of alpha-1 antitrypsin deficiency. Cureus, 10(10).
  • 10. Cheng, T., Li, Y., Pang, S., Wan, H. Y., Shi, G. C., Cheng, Q. J., ... & Huang, S. G. (2018). Emphysema extent on computed tomography is a highly specific index in diagnosing persistent airflow limitation: a real-world study in China. International Journal of Chronic Obstructive Pulmonary Disease, 13-26.